Cost effective solution for patient testing: Introducing comprehensive and affordable molecular diagnosis with verifiable accuracy.
San Diego, Calif., August 18, 2009 -- San Diego based MultiGEN Diagnostics Inc. has launched a novel multi-target DNA
sequencing technology (MultiGEN) for a wide range of clinical testing in molecular diagnostics.
“Until now, lack of a single testing platform has resulted in fragmenting the diagnostic market,
forcing laboratories to adopt number of alternative methods such as traditional culture, serology
and probe based DNA testing,” says Dr.Moorthy, President and Founder of MultiGEN
Diagnostics. “Present test methods have increased cost of testing, and hence all clinically
relevant targets are not tested routinely. The use of a single reliable and versatile single
platform technology (MultiGEN) for testing diverse clinical sample unifies testing procedures
and reduces cost significantly. “MultiGEN’s unique features will exceed end-user
expectations, and thereby encourage further use of molecular diagnostics in clinical markets,”
says Dr. Moorthy.
MultiGEN’s patented platform technology allows detection and confirmation of multiple targets
simultaneously using unmatched DNA sequencing, while still maintaining the highest possible
sensitivity and specificity. These tests include- panels for common pathogens causing an
infectious syndrome (e.g. STDs - sexually transmitted diseases), acquired mutations in cancer
that affect the response to drugs (e.g. K-ras, EGFR mutations for colo-rectal cancer therapy),
and genetic predisposition to disease (e.g. Thrombophilia panel with Factor V, Prothrombin,
MTHFR for clotting disorders).
Dr. Roger Hodkinson, a clinical pathologist with MultiGEN Diagnostics comments, “MultiGEN
is pioneering the concept of ‘Syndrome Driven’TM test panels for the simultaneous detection of
multiple DNA targets”. He further adds, “The proprietary test platform has verifiable accuracy,
and with its automated off-the-shelf liquid handling systems and genetic analyzers, it enables to
decrease the hands-on technical time, minimize human error, and reduce the overall cost”.
“MultiGEN Diagnostics accepts a variety of samples for its tests including buccal swabs, and
the results are reported within a day. “This platform technology is flexible enough to launch new
test menus within weeks, and detect ever changing microbial virulence, including H1N1, HIV,
and MRSA,” says Dr. Linda Wasserman, Medical Director of MultiGen Diagnostics.
Contact : Dr.T.V.Moorthy
Telephone: (858 ) 523 1313